Bio-Thera Out-Licenses Ex-China Rights for Avastin Biosimilar to Sandoz

Bio-Thera Solutions out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz. Sandoz will also have rights in most other countries not already assigned. In 2020, Bio-Thera filed BLAs for BAT1706 in these countries, plus China . Financial details of the agreement were not disclosed but, last year, Bio-Thera out-licensed China rights for the candidate to BeiGene in a $165 million deal. Bio-Thera is headquartered in  Guangzhou . More details.... Stock Symbols: (SHA: 688177) Share this with colleagues: // //